Thymosin Fraction V and Intensive Combination Chemotherapy: Prolonging the Survival of Patients With Small-Cell Lung Cancer
Cohen M, Chretien P, Ihde D, Fossieck B, Makuch R, Bunn P, Johnston A, Shackney S, Matthews M, Lipson S, Kenady D, Minna J. Thymosin Fraction V and Intensive Combination Chemotherapy: Prolonging the Survival of Patients With Small-Cell Lung Cancer. JAMA 1979, 241: 1813-1815. DOI: 10.1001/jama.1979.03290430031019.Peer-Reviewed Original ResearchThymosin fraction VIntensive remission induction chemotherapySmall cell bronchogenic carcinomaSmall cell lung cancerComplete response rateRemission induction chemotherapyWeeks of chemotherapyIntensive combination chemotherapySurvival of patientsRelapse-free survivalThymosin administrationThymosin treatmentComplete respondersCombination chemotherapyBronchogenic carcinomaImmune deficitsLung cancerSurvival durationSurvival timeTreatment groupsResponse rateChemotherapyPatientsFraction VTreatmentThymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer.
Cohen M, Chretien P, Ihde D, Fossieck B, Makuch R, Bunn P, Johnston A, Shackney S, Matthews M, Lipson S, Kenady D, Minna J. Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer. JAMA 1979, 241: 1813-5. PMID: 219267, DOI: 10.1001/jama.241.17.1813.Peer-Reviewed Original ResearchConceptsThymosin fraction VIntensive remission induction chemotherapySmall cell bronchogenic carcinomaSmall cell lung cancerComplete response rateRemission induction chemotherapyWeeks of chemotherapyIntensive combination chemotherapySurvival of patientsRelapse-free survivalThymosin administrationThymosin treatmentComplete respondersCombination chemotherapyBronchogenic carcinomaImmune deficitsLung cancerSurvival durationSurvival timeTreatment groupsResponse rateChemotherapyPatientsFraction VTreatment